ASGCT 2021 | DARIC33: CAR T with an on/off switch

Jacob Appelbaum, MD, PhD, University of Washington, Seattle, WA, describes the mechanism of action of dimerizing agent regulated immunoreceptor complex targeting CD33 (DARIC33) technology, a bioengineered T cell therapy currently being investigated for acute myeloid leukemia (AML). In DARIC33, the T cell signaling and antigen binding domains of a chimeric antigen receptor (CAR) are separated and a heterodimerizing unit responsive to rapamycin (RAPA) is embedded, allowing the anti-AML activity of the CAR T cell to be turned on and off in response to RAPA. This interview took place during the American Society for Cell & Gene Therapy 24th Annual Meeting 2021.